Gilead Sciences, Inc. (NASDAQ:GILD) is the world’s foremost biopharmaceutical company when it comes to combating deadly virus.
Keep Reading →
March 8 - News
A common trap many investors fall into is becoming overly confident in their views. This leads to wagering too much on a single outcome.
Keep Reading →
March 7 - News
One thing's for sure: You'll never discover truly great investments unless you actively look for them.
Keep Reading →
March 7 - News
Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap.
Keep Reading →
March 7 - News
Eight months ago, Bayer and Johnson & Johnson (NYSE:JNJ) announced that the Food and Drug Administration had issued a complete response letter for their anticoagulant, Xarelto...
Keep Reading →
March 6 - News
Last year will long be remembered for its remarkable advances in the diagnosis and prevention of HIV; OraSure Technologies gained FDA approval for the first-ever at-home, over...
Keep Reading →
March 6 - News
Are we beating up too much on Eli Lilly & Co.
Keep Reading →
March 6 - News
Investing in the health care sector isn't easy.
Keep Reading →
March 5 - News
It's official: With today's surge, the Dow Jones Industrial Average has hit a new all-time high.
Keep Reading →
March 5 - News
The market has been less than thrilled about an upcoming Supreme Court decision on the legality of the best-selling analytical test of Myriad Genetics, Inc. (NASDAQ:MYGN) .
Keep Reading →
March 5 - News
Do good things come in small packages for big pharma? Most of investors' attention is given to blockbuster drugs and drugs that have the potential to be blockbusters.
Keep Reading →
March 5 - News
Hello and welcome, readers. I’d like to issue an informal apology for the delay in writing in recent weeks.
Keep Reading →
March 4 - News
Investors are always trying to find the right balance between risk andreward.
Keep Reading →
March 4 - News
Celgene Corporation (NASDAQ:CELG) has good news -- and it has bad news.
Keep Reading →
March 4 - News
Mirror, mirror, on the wall, who's the frailest big pharma of all? The patent cliff has certainly taken its toll over the past couple of years, weakening several successful pharmaceutical...
Keep Reading →
March 1 - News
Celgene Corporation (NASDAQ:CELG) shareholders didn't have to wait long for good news in 2013. On Jan.
Keep Reading →
February 26 - News
Every investor can appreciate a stock that consistently beats the Street without getting ahead of its fundamentals and risking a meltdown.
Keep Reading →
February 26 - News
Are Bristol Myers Squibb Co. (NYSE:BMY) and Eli Lilly & Co.
Keep Reading →
February 25 - News
One of the aspects that makes investing so interesting is the enormous impact psychology has on results (and profits) people achieve (or don’t). What makes this so fascinating...
Keep Reading →
February 25 - News
A SWOT analysis is a look at a company’s strengths, weaknesses, opportunities, and threats, and is a tremendous way to gain a detailed and thorough perspective on a company ...
Keep Reading →
February 25 - Dividend Stocks
The Dow Jones Industrial Average finished strong last week, and eked out a closing price just above the 14,000 mark.
Keep Reading →
February 25 - News
Recently, Keryx Biopharmaceuticals (NASDAQ:KERX) achieved a new milestone as the company declared remarkable results from its Phase 3 trials of Zerenex.
Keep Reading →
February 25 - News
A SWOT analysis is a look at a company’s strengths, weaknesses, opportunities, and threats, and is a great way to gain a detailed and thorough perspective on a company and its...
Keep Reading →
February 23 - News
It's been a riveting week for investors. After starting the shortened week up by 54 points on Tuesday, the Dow Jones Industrial Average proceeded to crater.
Keep Reading →
February 22 - News
Although spin-off situations offered investors compelling investment opportunities most of the time, investors should study each situation quite carefully to determine its own...
Keep Reading →
February 22 - News
All throughout Wall Street we keep hearing about Amarin Corporation plc (ADR) (NASDAQ:AMRN) being bought out by some type of Big Pharma company in the future. It's all rumors...
Keep Reading →
February 22 - News
Merck & Co., Inc. (NYSE:MRK) has to more heavily rely on top selling pharmaceuticals now that Singulair's off patent.
Keep Reading →
February 22 - News
Analysts wonder if other drug companies will follow in the footsteps of Abbott Laboratories (NYSE:ABT) and spinoff different parts of their business.
Keep Reading →
February 21 - News
Stock buybacks are generally considered a bullish signal on Wall Street.
Keep Reading →
February 21 - News
I am always on the hunt to pick up those stocks which the investment managers are betting upon aggressively.
Keep Reading →
February 21 - News
One thing's for sure: You'll never discover truly great investments unless you actively look for them.
Keep Reading →
February 20 - News
We spend more money on our pets than ever before. Fido pulls on our heartstrings and out pop our wallets.
Keep Reading →
February 20 - News
Neither company has a stellar track record when it comes to dividends.
Keep Reading →
February 19 - Dividend Stocks
Earnings season is now starting to wind down, with most companies already having reported their quarterly results.
Keep Reading →
February 19 - News
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) started the year strong with a Food and Drug Administration approval for genetic high cholesterol drug Kynamro.
Keep Reading →
February 19 - News
Make no bones about it -- Zoetis Inc (NYSE:ZTS) is one expensive stock. It even might be the most expensive health-care stock for its size.
Keep Reading →
February 19 - News
Shares of Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) have risen by more than 35% since last Thursday.
Keep Reading →
February 19 - News
It's now more than halfway through the period that Eli Lilly & Co. (NYSE:LLY) has called its "years YZ," a term describing the years spanning from 2011 to 2014.
Keep Reading →
February 19 - News
Pfizer Inc. (NYSE:PFE) faced a rough 2012 after Lipitor's loss of exclusivity in November 2011.
Keep Reading →
February 18 - News
Research firm Decision Resources predicts that the rheumatoid arthritis market will modestly grow to $15 billion in the next decade.
Keep Reading →
February 18 - News
Pfizer Inc. (NYSE:PFE) recently spun off animal health firm Zoetis Inc (NYSE:ZTS) in the form of an IPO.
Keep Reading →
February 15 - News
Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap.
Keep Reading →
February 15 - News
It's Friday afternoon on Wall Street, and investors seem content with their holdings going into the three-day weekend.
Keep Reading →
February 15 - News
Investors look to the Dow Jones Industrials as the strongest blue-chip stocks the U.S. has to offer.
Keep Reading →
February 15 - News
The Dow Jones Industrial Average (INDEX:.DJI) has had a wild ride this morning, but stayed up nevertheless.
Keep Reading →
February 15 - News
The biotechnology industry is one of the most attractive industries for investors primarily due to its high returns.
Keep Reading →
February 14 - News
Some of the best-performing stocks over the past several decades boast long histories of paying dividends to shareholders. Moreover, if these stocks sell for an apparent discount...
Keep Reading →
February 14 - News
Back in 2011, generic drug giant Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) dominated the MS field, riding the coattails of its Copaxone medication to success.
Keep Reading →
February 14 - News
